Tom Scarlett has been an investment analyst for more than 20 years. He has written for Personal Finance, Utility Forecaster, Forecast and Strategies, Global Investing and other publications. He has also been an editor at Bloomberg BNA and Thompson Publishing.
Recent Articles By The Author
HCP: Real Estate, Real Profits and a Real Health Care Market Edge
Which REIT is the best choice for today's investors?
Nucor Momentum Likely to Continue Amidst Strong Sales, Favorable Trends
The North Carolina-based company is the largest steel manufacturer in the U.S.
Paychex Payroll Services Are a Likely Constant Even in Chaotic Times
This steady performer has a strong business in the small- to medium-sized company segment, which accounts for over half the jobs in the U.S.
Here Is Why Dominion Resources Is a Superb Power Play Right Now
The combination of growth and income prospects makes this stock attractive.
Alcoa, Arconic Benefiting From Rising Demand for Strong, Lightweight Materials
Alcoa is probably a better retirement investment, while Arconic carries more risk.
Allergan Rebounding With Strong Product Pipeline, Smart Acquisitions
The pharmaceutical company's new strategy emphasizes new product launches and international expansion.
Oilfield Services Company Schlumberger Is Poised to Remain on Top
The world's leading company in its sector shows no signs of relinquishing its position and continues to flex its muscles.
Data Storage Provider Seagate's Adaptability Leading to Increased Profits
Many remote servers that are critical to cloud computing systems rely on Seagate techology.
Regardless of Judge's Decision on Humana Deal, Aetna Is Pointing Upward
U.S. District Court Judge John Bates, a Republican appointee, is scheduled to rule on Aetna's proposed $37 billion acquisition of rival Humana later this month.
Drugstore Chain CVS Poised for a Rebound
CVS has cash on hand and is benefiting from recent acquisitions.